Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study

[1]  H. Bauchner,et al.  Expression of concern: Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011:129(7):914-920. , 2015, JAMA ophthalmology.

[2]  D. Roth,et al.  EFFICACY AND SAFETY OF TWO OR MORE DEXAMETHASONE INTRAVITREAL IMPLANT INJECTIONS FOR TREATMENT OF MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION (SHASTA STUDY) , 2014, Retina.

[3]  Y. Buys,et al.  Intraocular pressure monitoring post intravitreal steroids: a systematic review. , 2013, Survey of ophthalmology.

[4]  G. Pertile,et al.  Intravitreal Dexamethasone Implant (Ozurdex) for macular edema secondary to retinal vein occlusion: a comparative study between recent onset and chronic edema , 2013 .

[5]  P. Campochiaro,et al.  Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. , 2013, Ophthalmology.

[6]  G. Querques,et al.  Repeated Intravitreal Dexamethasone Implant (Ozurdex®) for Retinal Vein Occlusion , 2012, Ophthalmologica.

[7]  D. Denis,et al.  Repeated Treatment for Macular Edema in Vein Occlusion by Intravitreal Implant of Dexamethasone , 2012, Case Reports in Ophthalmology.

[8]  P. Mitchell,et al.  Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. , 2012, Ophthalmology.

[9]  G. Jaffe,et al.  Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. , 2012, Ophthalmology.

[10]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[11]  I. Kim,et al.  Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. , 2011, American journal of ophthalmology.

[12]  U. Kompella,et al.  Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. , 2011, Archives of ophthalmology.

[13]  G. Soubrane,et al.  Management of Retinal Vein Occlusion – Consensus Document , 2011, Ophthalmologica.

[14]  D. Goldstein,et al.  Dexamethasone for ocular inflammation , 2011, Expert opinion on pharmacotherapy.

[15]  S. Whitcup,et al.  Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. , 2010, Investigative ophthalmology & visual science.

[16]  P. Wiedemann,et al.  Retinal vein thrombosis: pathogenesis and management , 2010, Journal of thrombosis and haemostasis : JTH.

[17]  M. Kahook,et al.  Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents , 2010, British Journal of Ophthalmology.

[18]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[19]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[20]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[21]  D. Heo,et al.  Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line. , 2010, Oncology reports.

[22]  E. Boscolo,et al.  Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. , 2010, The New England journal of medicine.

[23]  R. Forte,et al.  Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume , 2009, Eye.

[24]  E. Lobenhofer,et al.  Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells , 2009, BMC Medical Genomics.